90085-61-3

Upstream product

• 23860-35-7 cyclohexylacetic acid chloride 
• 5292-21-7 Cyclohexylacetic acid 

Downstream Products

• 58851-63-1 Brom-cyclohexylessigsaeure-methylester 
• 92250-42-5 2-cyclohexyl-4H-benzo[1,4]oxazin-3-one 
• 327985-56-8 3-cyclohexyl-8-(2-fluorophenyl)-5-methyl-2-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)imidazo[1,2-d][1,2,4]triazine 
• 1162677-57-7 2-[2-(4-chloro-phenyl)-5,6-difluoro-benzoimidazol-1-yl]-2-cyclohexyl-N-trans-(4-hydroxy-cyclohexyl)-acetamide 
• 1162677-43-1 2-[2-(4-chloro-phenyl)-5,6-difluoro-benzoimidazol-1-yl]-2-cyclohexyl-N-[2-fluoro-4-(1H-tetrazol-5-yl)-phenyl]-acetamide 
• 1162675-66-2 [2-(4-chloro-phenyl)-5,6-difluoro-benzoimidazol-1-yl]-cyclohexyl-acetic acid 
• 1162676-07-4 [2-(4-chloro-phenyl)-benzoimidazol-1-yl]-cyclohexyl-acetic acid 
• 1162676-06-3 [2-(4-chloro-phenyl)-benzoimidazol-1-yl]-cyclohexyl-acetic acid ethyl ester 
• 1162675-80-0 [2-(4-chloro-phenyl)-5,6-difluoro-benzoimidazol-1-yl]-cyclohexyl-acetic acid ethyl ester 
• 367281-32-1 3-cyclohexyl-7-(2-fluorophenyl)-4-methyl-2-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)pyrazolo[1,5-d][1,2,4]triazine 
• 900535-69-5 1-[(1-(4-chloro-benzyl)-2-{4-[1-cyclohexyl-2-(2,5-dioxo-pyrrolidin-1-yl)-ethyl]-piperazin-1-yl}-2-oxo-ethylcarbamoyl)-methyl]-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester 
• 900535-67-3 1-[(1-(4-chloro-benzyl)-2-{4-[1-cyclohexyl-2-(ethyl-methanesulfonyl-amino)-ethyl]-piperazin-1-yl}-2-oxo-ethylcarbamoyl)-methyl]-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester 
• 900535-68-4 1-{[2-{4-[2-(acetyl-ethyl-amino)-1-cyclohexyl-ethyl]-piperazin-1-yl}-1-(4-chloro-benzyl)-2-oxo-ethylcarbamoyl]-methyl}-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester 
• 900535-66-2 1-({1-(4-chloro-benzyl)-2-[4-(1-cyclohexyl-2-methanesulfonylamino-ethyl)-piperazin-1-yl]-2-oxo-ethylcarbamoyl}-methyl)-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties

Structure-guided lead optimization of recently described benzimidazolyl acetamides addressed the key liabilities of the previous lead compound 1. These efforts culminated in the discovery of 4-{(S)-2-[2-(4-chloro-phenyl)-5,6- difluoro-benzoimidazol-1-yl]-2-cyclohexyl-acetylamino}-3-fluoro-benzoic acid 7g, a highly potent and selective FXR agonist with excellent physicochemical and ADME properties and potent lipid lowering activity after oral administration to LDL receptor deficient mice.

Privileged structure based ligands for melanocortin-4 receptors-Aliphatic piperazine derivatives

Aliphatic carbocyclic replacement of the benzyl group of compound 1 yielded compounds with high affinity for the melanocortin-4 receptor (MC4R). Compounds with a cyclohexyl group showed a consistent high affinity, while different polar groups with less basicity were good replacements for the original diethyl amines. Substitution of the polar group found in these privileged structures with an aliphatic moiety produced compounds with high affinity for MC4R.